Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Lowers Holdings in Kenvue Inc. $KVUE

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 32.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 36,051 shares of the company’s stock after selling 16,952 shares during the quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group’s holdings in Kenvue were worth $755,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. GAMMA Investing LLC boosted its position in Kenvue by 33.2% in the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock valued at $594,000 after buying an additional 6,169 shares during the period. Cambridge Investment Research Advisors Inc. boosted its holdings in Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock valued at $2,545,000 after purchasing an additional 4,034 shares during the period. Golden State Wealth Management LLC boosted its holdings in Kenvue by 292.0% in the first quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company’s stock valued at $74,000 after purchasing an additional 2,295 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in Kenvue by 2.6% in the first quarter. Robeco Institutional Asset Management B.V. now owns 103,091 shares of the company’s stock valued at $2,472,000 after purchasing an additional 2,576 shares during the period. Finally, Creative Financial Designs Inc. ADV boosted its holdings in Kenvue by 218.1% in the first quarter. Creative Financial Designs Inc. ADV now owns 4,523 shares of the company’s stock valued at $108,000 after purchasing an additional 3,101 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on KVUE shares. Royal Bank Of Canada decreased their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Evercore ISI decreased their price objective on Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a research note on Tuesday, September 23rd. The Goldman Sachs Group decreased their price target on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, October 2nd. JPMorgan Chase & Co. decreased their price target on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Finally, Canaccord Genuity Group decreased their price target on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.75.

Kenvue Price Performance

KVUE stock opened at $15.00 on Monday. The business has a 50 day moving average price of $17.91 and a 200 day moving average price of $20.79. The stock has a market cap of $28.78 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 2.16 and a beta of 0.72. Kenvue Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm’s revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 5.5%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s dividend payout ratio is presently 112.16%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.